Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early intensified ketamine-based treatment versus usual second-line care for major depressive disorder after first-line treatment failure
ACTRN12625000329460Phase 3Not yet recruiting
- Sponsor
- Northern Adelaide Local Health Network
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ketamine in major depressive disorder (MDD) (2 arms), sponsored by Northern Adelaide Local Health Network. Primary endpoint: Change in symptom severity. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12625000329460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000329460.